Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to psoriasis severity. Materials and methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients received placebo, 80-mg ixekizumab every 2 weeks (IXEQ2W), every 4 weeks (IXEQ4W)...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2018.1473551 |